Alessandro Doria

Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.

Mariam A, Miller-Atkins G, Pantalone KM, Zimmerman RS, Barnard J, Kattan MW, Shah H, McLeod HL, Doria A, Wagner MJ, Buse JB, Motsinger-Reif AA, Rotroff DM.

Diabetes Care. 2021 Apr 16. PMID: 33863751

Autosomal dominant diabetes associated with a novel ZYG11A mutation resulting in cell cycle arrest in beta-cells.

Charoensuk C, Thamtarana PJ, Chanprasert C, Tangjittipokin W, Shirakawa J, Togashi Y, Orime K, Songprakhon P, Chaichana C, Abubakar Z, Ouying P, Sujjitjoon J, Doria A, Plengvidhya N, Yenchitsomanus PT.

Mol Cell Endocrinol. 2021 02 15. 522:111126. PMID: 33321115

Disentangling the heterogeneity of adulthood-onset non-autoimmune diabetes: a little closer but lot more to do.

Trischitta V, Prudente S, Doria A.

Curr Opin Pharmacol. 2020 12. 55:157-164. PMID: 33271410

Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial.

Tang Y, Shah H, Bueno Junior CR, Sun X, Mitri J, Sambataro M, Sambado L, Gerstein HC, Fonseca V, Doria A, Pop-Busui R.

Diabetes Care. 2021 Jan. 44(1):164-173. PMID: 33144354

Allopurinol and Chronic Kidney Disease. Reply.

Doria A, Galecki AT, Mauer M.

N Engl J Med. 2020 10 22. 383(17):1690-1691. PMID: 33085876

Association of the 1q25 Diabetes-Specific Coronary Heart Disease Locus With Alterations of the ?-Glutamyl Cycle and Increased Methylglyoxal Levels in Endothelial Cells.

Pipino C, Shah H, Prudente S, Di Pietro N, Zeng L, Park K, Trischitta V, Pennathur S, Pandolfi A, Doria A.

Diabetes. 2020 10. 69(10):2206-2216. PMID: 32651240

Uric acid and risk of diabetic kidney disease.

Mauer M, Doria A.

J Nephrol. 2020 Oct. 33(5):995-999. PMID: 32651849

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.

Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M.

N Engl J Med. 2020 06 25. 382(26):2493-2503. PMID: 32579810

Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes.

Morieri ML, Shah HS, Tang Y, Doria A.

J Am Coll Cardiol. 2020 06 16. 75(23):2995-2996. PMID: 32527409

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

Morieri ML, Shah HS, Sjaarda J, Lenzini PA, Campbell H, Motsinger-Reif AA, Gao H, Lovato L, Prudente S, Pandolfi A, Pezzolesi MG, Sigal RJ, Paré G, Marcovina SM, Rotroff DM, Patorno E, Mercuri L, Trischitta V, Chew EY, Kraft P, Buse JB, Wagner MJ, Cresci S, Gerstein HC, Ginsberg HN, Mychaleckyj JC, Doria A.

Diabetes. 2020 04. 69(4):771-783. PMID: 31974142